Start a ProjectMICRONEEDLE APPLICATION
Project inputs include antigen format, target dose, adjuvant strategy, available potency or activity methods, temperature and moisture sensitivity, intended population and target product pathway. Sterility and aseptic requirements must be defined with the sponsor rather than assumed.
Program-specific questions may include antigen integrity, loading distribution, insertion and delivery, release, residual payload, storage stability and manufacturing controls. Immunogenicity or clinical benefit requires appropriately designed studies outside routine formulation screening.
Coated microneedles can be considered for low-dose surface loading and dissolving microneedles for matrix-incorporated delivery. Selection depends on antigen stability, dose, release needs, patch design and scalable process controls.
Stage outputs can include feasibility conclusions, a candidate loading strategy, prototype characterization, analytical and delivery observations, development risks and a next-stage study plan. They are not regulatory approval or clinical-efficacy conclusions.
A CASMN-affiliated publication evaluated a tip-loaded dissolving microneedle peptide-vaccine model. The model and study conditions are stated as research evidence and cannot be generalized to other antigens or commercial products.
CASMN evaluates vaccine-related programs on a project-specific basis. Technical Review — Reviewed by: CASMN R&D Team · Last reviewed: August 2026.
The team reviews payload properties, target dose, stability, intended use, delivery requirements and manufacturing constraints.
Technology selection is made project by project after reviewing dose, release profile, product use and process requirements.
No. Publications provide scientific context and do not establish regulatory approval, clinical performance or commercial availability.
Send your target product, payload, development stage and cooperation scope to our business development team.
Start a Project